Medical device market research essentials

Who actually buys a medical device

In most hospital settings the clinician chooses and the institution buys, and researching only one half produces a forecast that misses. The clinician's decision is about whether the device performs in their hands, in their procedure, with their team. The institution's decision is about total cost of ownership, contract terms, standardisation across the system and whether the clinical benefit is evidenced well enough to justify the spend.

That second decision is usually made by a value analysis committee or equivalent, drawing in materials management, hospital pharmacy where relevant, finance, biomedical engineering, infection control and sometimes nursing leadership. Each has a veto in practice, and each weighs different evidence. Map that committee's composition for your target accounts before you design the study, because the person who will block the purchase is often not on the original respondent list.

Clinician preference research

Clinician preference remains the primary driver of device choice, and it is largely tacit knowledge. Surgeons and proceduralists make judgements about handling, tactile feedback, visualisation, deployment confidence, set-up time and how the device behaves when a case goes badly — none of which they articulate well in a questionnaire, because the knowledge lives in their hands rather than in their stated reasons.

Capture it with methods that get close to the procedure: simulated use on a bench or cadaveric model, video-based review of a recorded procedure, in-theatre observation where permissions allow, and interviews conducted immediately after a case rather than weeks later. Then triangulate stated preference against observed behaviour. Where they diverge, the divergence is usually the finding — and the thing a competitor has already exploited.

Value analysis committees and procurement

Value analysis committees exist to control variation and cost, and they assess total cost of ownership rather than unit price: consumables and disposables, reusable instrument sets and their reprocessing, training and proctoring, service contracts and uptime, integration with existing capital, and disposal. A device that is cheaper per unit and more expensive to run will frequently lose, and clinicians are often unaware of the line items driving the decision.

Research these audiences on process as well as criteria. Establish the submission route, who sponsors a new product internally, what evidence package is expected, the committee's meeting cadence, the trial or evaluation period typically required, and how group purchasing agreements, tenders or rate contracts constrain what can even be considered. Adoption timelines in medtech are set by those cycles far more than by clinical enthusiasm.

Reimbursement, coding and coverage

A device with no clear payment route struggles regardless of clinical merit, because someone has to be paid for the procedure it is used in. Validate three things with payers and hospital finance: which existing code the procedure falls under or whether a new one is needed, whether coverage policy includes the indication, and whether the payment level leaves the hospital whole once the device cost is absorbed.

Where a product sits inside a bundled payment or a scheme package rate, the device cost competes directly with the hospital's margin on the episode, which changes the conversation entirely. In India, package rates under Ayushman Bharat PM-JAY and state schemes play exactly this role, and empanelment conditions shape where a procedure can be performed at all. Research the economics at episode level, not at device level.

Methods that suit device research

The device toolkit leans more observational and more hands-on than the pharma toolkit, because the behaviour being studied is physical and procedural.

• Simulated use and bench or cadaveric labs — the closest safe approximation to real handling.
• In-theatre and in-clinic observation — workflow, set-up, team interaction and failure modes as they actually occur.
• Video ethnography and recorded procedure review — lets clinicians narrate decisions they cannot describe in the abstract.
• Post-case interviews — conducted while the detail is still fresh rather than recalled weeks later.
• Value analysis committee and procurement interviews — process, criteria, evidence expectations and timelines.
• Conjoint analysis on device attributes — trades handling, service, training burden, consumable cost and price against each other.
• Capital planning and budget cycle interviews with hospital finance — for equipment with multi-year approval horizons.

Regulatory context and claims

Device regulation bounds what research may legitimately explore. A device's classification, approved indications and labelling differ by market, and fieldwork must not probe or imply unapproved use. In India, medical devices are regulated by CDSCO under the Medical Devices Rules with a risk-based classification, and the applicable class affects both evidence expectations and procurement scrutiny.

Vigilance obligations apply as they do in pharma. Device malfunctions, use errors and patient harm mentioned by a respondent must be routed to the client's vigilance function inside the agreed window — and in device research this happens more often than teams expect, because asking clinicians about handling naturally surfaces stories about things going wrong.

Devices in India

India's device market spans imported premium equipment in corporate hospital chains and highly price-competitive domestic manufacturing, with procurement routes that differ sharply by setting. Corporate chains run formal evaluation and increasingly centralised purchasing; standalone nursing homes buy through the owner-clinician with far shorter cycles; government institutions buy through tenders and rate contracts with specification-led selection.

Research design should follow those routes rather than assume one buying process. Include distributors and dealers, who carry real influence over which products reach smaller accounts and who often provide training and service in practice. And test affordability at episode level against scheme package rates, because a device justified by long-term outcomes may still fail a hospital's arithmetic on a fixed-rate procedure.

Common mistakes

The commonest error is researching surgeons alone and forecasting as though their preference were the purchase decision. The second is relying on stated preference for attributes that are physical — asking about handling in a survey measures vocabulary, not performance. The third is pricing a device on unit cost without modelling consumables, training, service and reprocessing, which is how committees actually evaluate it.

Two further mistakes are specific to timing. Ignoring capital and tender cycles produces adoption curves that are directionally right and completely wrong on dates. And validating reimbursement late — after a forecast has been built on an assumed code and payment level — turns a research gap into a commercial write-down.